AXPAXLI's Phase 3 superiority over aflibercept sets up an NDA bet on whether FDA accepts SOL-1 data via 505(b)(2) and SOL-R confirms the profile

Bull

FDA accepts the 505(b)(2) NDA for filing and issues a standard review timeline, validating the agency's comfort with SOL-1 Week 52 data as sufficient for approval without requiring a fully company-sponsored active-controlled NDA package. A positive outcome would mean AXPAXLI — the first anti-VEGF agent to demonstrate superiority over aflibercept in wet AMD — moves toward a PDUFA date, unlocking the commercial ramp and significantly de-risking the thesis ahead of SOL-R confirmation.

Bear

FDA declines to accept the 505(b)(2) submission or issues a Refuse to File, citing insufficient data on the reference listed drug or demanding a traditional 505(b)(1) NDA with additional company-controlled comparator arms; alternatively, FDA may accept the filing but place a clinical hold or request additional manufacturing, safety, or durability data that extends the timeline materially. The most likely failure mode is regulatory uncertainty around whether SOL-1's single-arm superiority data against aflibercept — collected outside of a fully controlled OCUL-sponsored trial design — satisfies FDA's evidentiary bar for a new molecular entity in a competitive indication.